• Explore /
  • Poster
  • / FS-1502 in <em>HER2</em>-positive advanced breast cancer: Results from an open-label, phase 1 study.

FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

Abstract Poster

Authors

null

Qiao Li

Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Chaoyang District, China

Qiao Li , Ying Cheng , Zhongsheng Tong , Yunjiang Liu , Xian Wang , Min Yan , Jianhua Chang , Shusen Wang , Caiwen Du , Liang Li , Chunjiao Wu , Mingxia Wang , Zhuo Wang , Zhuli Wu , Yongli Jin , Yongjiao Zhang , Ai-Min Hui , Xingli Wang , Binghe Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Clinical Trial Registration Number

NCT03944499

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3044)

DOI

10.1200/JCO.2023.41.16_suppl.3044

Abstract #

3044

Poster Bd #

242

Abstract Disclosures

Similar Posters

First Author: Sara A. Hurvitz

First Author: Chunfang Hao

First Author: Sayeh Moazami Lavasani

First Author: Bob T. Li